Will A ‘Netflix’ Model Solve Antibiotic Reimbursement Challenges And Spur R&D?

In Vivo executive editor Lucie Ellis-Taitt and Infex CEO Peter Jackson explore the current state of antimicrobial resistance in the UK, and worldwide. They discuss the potential of a new “Netflix” style subscription model in the UK for antibiotic reimbursement, as well as future challenges for biotechs in the anti-infectives space.